In ovarian cancer, CCNE1 amplification is detected in about 20% of tumours, in a manner largely mutually exclusive with homologous recombination deficiency, and is enriched in platinum-refractory tumours2,5. This evidence concerns the gene CCNE1 and neoplasm.